Raymond James & Associates Has $58.85 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Raymond James & Associates increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.9% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 66,999 shares of the biopharmaceutical company’s stock after purchasing an additional 5,499 shares during the quarter. Raymond James & Associates owned approximately 0.06% of Regeneron Pharmaceuticals worth $58,845,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Sunbelt Securities Inc. acquired a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at about $25,000. Annis Gardner Whiting Capital Advisors LLC acquired a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at about $26,000. Fortitude Family Office LLC acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at about $31,000. Sutton Wealth Advisors Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 38.2% in the 3rd quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 13 shares during the last quarter. Finally, Bruce G. Allen Investments LLC bought a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $40,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 2,707 shares of the business’s stock in a transaction that occurred on Tuesday, January 23rd. The stock was sold at an average price of $950.00, for a total transaction of $2,571,650.00. Following the transaction, the director now owns 6,382 shares of the company’s stock, valued at $6,062,900. The sale was disclosed in a document filed with the SEC, which is available through this link. In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 2,707 shares of the business’s stock in a transaction that occurred on Tuesday, January 23rd. The stock was sold at an average price of $950.00, for a total transaction of $2,571,650.00. Following the transaction, the director now owns 6,382 shares of the company’s stock, valued at $6,062,900. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Marion Mccourt sold 1,000 shares of the business’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $934.71, for a total value of $934,710.00. Following the transaction, the executive vice president now directly owns 13,789 shares in the company, valued at approximately $12,888,716.19. The disclosure for this sale can be found here. Insiders have sold a total of 13,729 shares of company stock valued at $13,124,641 over the last 90 days. 8.83% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on REGN. Morgan Stanley raised their target price on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a research note on Wednesday, March 13th. Barclays lifted their price objective on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 23rd. TD Cowen lifted their price objective on shares of Regeneron Pharmaceuticals from $900.00 to $1,000.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 6th. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 5th. Finally, Truist Financial reissued a “buy” rating and set a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $967.59.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $966.30 on Thursday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69. The stock’s 50-day simple moving average is $957.54 and its 200 day simple moving average is $878.93. The company has a market cap of $106.06 billion, a P/E ratio of 27.81, a P/E/G ratio of 2.76 and a beta of 0.11. Regeneron Pharmaceuticals, Inc. has a 52-week low of $684.80 and a 52-week high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. The business had revenue of $3.43 billion for the quarter, compared to the consensus estimate of $3.29 billion. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. Regeneron Pharmaceuticals’s quarterly revenue was up .6% on a year-over-year basis. During the same quarter in the previous year, the business earned $10.96 earnings per share. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 38.75 EPS for the current fiscal year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.